An interventional study of Nurosym Device in Irritable Bowel Syndrome (IBS), sponsored by Hoag Memorial Hospital Presbyterian. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Hoag Memorial Hospital Presbyterian · Not applicable, Interventional, and Device feasibility
Randomized, single-blind, sham-controlled crossover study evaluating the efficacy and safety of transcutaneous auricular vagus nerve stimulation (taVNS) in adult patients with IBS. Two intervention groups will receive the investigational NurosymTM device and be randomized (1:1) to either the ACTIVE or SHAM crossover taVNS group. After randomization, participants will receive 8 weeks of active stimulation (ACTIVE) or 4 weeks of sham followed by 4 weeks of active stimulation (SHAM crossover).
1,084 studies on the registry are indexed under Irritable Bowel Syndrome; 196 are open to participants now.
This study's planned enrollment of 40 is below the median of 70 across 869 interventional studies indexed under Irritable Bowel Syndrome.
Browse Irritable Bowel Syndrome studies →Hoag Memorial Hospital Presbyterian is the lead sponsor of 33 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A diagnosis of IBS according to Rome IV criteria, as follows:
a. Recurrent abdominal pain, on average, at least 1 day per week in the last 3 months, associated with 2 or more of the following criteria: i. Related to defecation. ii. Associated with a change in stool frequency. iii. Associated with a change in stool from (appearance). b. Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis.
Exclusion Criteria:
Participants will receive 8 weeks of active stimulation (ACTIVE)
Device: Nurosym Device
Participants will receive 4 weeks of sham followed by 4 weeks of active stimulation
Device: Nurosym Device
Neuromodulation with Transcutaneous Auricular Vagus Nerve Stimulation
IBS-SSS
Change in the IBS-SSS from baseline (week 1) to the end of week 5 and week 9, and extended follow up at the end of week 21
Time frame: 21 Weeks
No study locations are listed for this record.
Plan to share: Undecided
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hoag Memorial Hospital Presbyterian